Published in Vaccine Weekly, March 10th, 2010
"Because of high HBIg costs and improving efficacy of new oral agents, there is increasing interest in HBIg discontinuation. To describe results of a protocol at our center including HBV vaccination and HBIg discontinuation. All...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly